… by heparin/LMWH, it is warranted to conduct clinical studies that evaluate therapeutic
doses of heparin/LMWH in COVID-19 patients. In addition, identification of specific heparin-derived …

… evidence for the use of full-dose heparin (ie, therapeutic rather than prophylactic dosing) as
… anticoagulant in COVID-19. We also discuss a subset of non-anticoagulant effects of heparin …

… with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose
anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with …

… of therapeutic anticoagulation in hospitalized patients with COVID-19 using heparin does …
modified guidelines for anticoagulation in patients hospitalized with COVID-19 based on the …

… between patients with and without receiving anticoagulant. So, how does this paper impact
the current management of COVID‐19 patients? Low molecular weight heparin (LMWH) at …

… requirement with any of the anticoagulants used. Conclusion We conclude that COVID-19+
patients with moderate or severe illness benefit from anticoagulation and that apixaban has …

… Anticoagulant treatment group was defined as receiving unfractionated heparin or low
molecular weight heparin (… commonly used anticoagulant therapy for COVID‐19 in our hospital. …

… We used the predefined search terms: (COVID-19 OR coronavirus disease 2019 OR severe
acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)) AND (heparin OR enoxaparin OR …

… heparin is associated with decreased COVID-19 mortality. Because patients with COVID-19 …
of low-dose or full-dose prophylactic anticoagulants would result in net benefit or harm. …

… , in COVID-19 infections caused by the novel coronavirus (SARS-CoV-2), heparin anticoagulant
… In other words, abnormal coagulation may influence the prognosis of COVID-19. This is …